These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 11200072

  • 1. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ.
    J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
    [Abstract] [Full Text] [Related]

  • 2. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G.
    Clin Cancer Res; 2005 Feb 15; 11(4):1490-9. PubMed ID: 15746051
    [Abstract] [Full Text] [Related]

  • 3. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F, Hermann P, Nakashima K, Matsukawa S, Sakai K, Bacon KB.
    Eur J Immunol; 2003 Jun 15; 33(6):1576-85. PubMed ID: 12778475
    [Abstract] [Full Text] [Related]

  • 4. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G.
    J Leukoc Biol; 2002 Jul 15; 72(1):83-92. PubMed ID: 12101266
    [Abstract] [Full Text] [Related]

  • 5. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM, Cutro S, Hu J, Marzouk A, Marshall JD.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2057-68. PubMed ID: 17161362
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
    Chen W, Yu Y, Shao C, Zhang M, Wang W, Zhang L, Cao X.
    Immunol Lett; 2001 May 01; 77(1):17-23. PubMed ID: 11348665
    [Abstract] [Full Text] [Related]

  • 7. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C.
    Blood; 2000 Feb 01; 95(3):999-1006. PubMed ID: 10648415
    [Abstract] [Full Text] [Related]

  • 8. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S.
    Eur J Immunol; 2003 Jun 01; 33(6):1633-41. PubMed ID: 12778481
    [Abstract] [Full Text] [Related]

  • 9. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
    Rieger R, Kipps TJ.
    Cancer Res; 2003 Jul 15; 63(14):4128-35. PubMed ID: 12874017
    [Abstract] [Full Text] [Related]

  • 10. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
    Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, Viora M.
    J Leukoc Biol; 2009 Aug 15; 86(2):261-71. PubMed ID: 19401392
    [Abstract] [Full Text] [Related]

  • 11. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM.
    Eur J Immunol; 2004 Jan 15; 34(1):251-62. PubMed ID: 14971051
    [Abstract] [Full Text] [Related]

  • 12. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ.
    J Leukoc Biol; 2005 Mar 15; 77(3):378-87. PubMed ID: 15582984
    [Abstract] [Full Text] [Related]

  • 13. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM.
    J Leukoc Biol; 2004 Sep 15; 76(3):585-93. PubMed ID: 15218053
    [Abstract] [Full Text] [Related]

  • 14. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.
    Teleshova N, Kenney J, Williams V, Van Nest G, Marshall J, Lifson JD, Sivin I, Dufour J, Bohm R, Gettie A, Pope M.
    J Leukoc Biol; 2006 Feb 15; 79(2):257-67. PubMed ID: 16443827
    [Abstract] [Full Text] [Related]

  • 15. Porcine-specific CpG-oligodeoxynucleotide activates B-cells and increases the expression of MHC-II molecules on lymphocytes.
    Van der Stede Y, Verdonck F, Verfaillie T, Goddeeris BM, Cox E.
    Vet Immunol Immunopathol; 2005 May 01; 105(1-2):115-24. PubMed ID: 15797481
    [Abstract] [Full Text] [Related]

  • 16. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
    Weiner GJ.
    Adv Drug Deliv Rev; 2009 Mar 28; 61(3):263-7. PubMed ID: 19168102
    [Abstract] [Full Text] [Related]

  • 17. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
    Buhé V, Guerrier T, Youinou P, Berthou C, Loisel S.
    Ann N Y Acad Sci; 2009 Sep 28; 1173():858-64. PubMed ID: 19758238
    [Abstract] [Full Text] [Related]

  • 18. Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B.
    Li N, Fan XG, Chen ZH, Huang Y, Quan J, Liu ZB.
    APMIS; 2005 Oct 28; 113(10):647-54. PubMed ID: 16309422
    [Abstract] [Full Text] [Related]

  • 19. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
    Brummel R, Roberts TL, Stacey KJ, Lenert P.
    Eur J Immunol; 2006 Jul 28; 36(7):1951-62. PubMed ID: 16791898
    [Abstract] [Full Text] [Related]

  • 20. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death.
    Sohn WJ, Lee KW, Choi SY, Chung E, Lee Y, Kim TY, Lee SK, Choe YK, Lee JH, Kim DS, Kwon HJ.
    Mol Immunol; 2006 Mar 28; 43(8):1163-71. PubMed ID: 16122803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.